

Table S1 Risk stratification of patients at the time of relapse according to the EuroNet PHL-C1 recommendations (9)

Low-risk	Standard-risk
<ul style="list-style-type: none"> • Early relapse after a maximum of 4 cycles of first-line chemotherapy • Late relapse after a maximum of 6 cycles of first-line chemotherapy <p>And all the following:</p> <ul style="list-style-type: none"> • Stage at relapse is I–III • No previous radiotherapy or relapse only outside the previous radiotherapy field • No excessive radiotherapy fields required in salvage • Complete response after two cycles of salvage treatment with DS 1, 2, 3 	<ul style="list-style-type: none"> • Primary refractory HL • Early Relapse after more than four cycles of first-line chemotherapy • Stage IV at relapse • Relapse in a previous radiotherapy field. • Relapse that requires radiotherapy in salvage that is considered as having severe toxicity • Patients with low-risk criteria who failed to achieve an adequate response after two cycles of salvage treatment

HL, Hodgkin lymphoma.

Table S2 Patients' characteristics, at initial presentation, relapse, response to IGEV and outcome

Patient number	Initial age (years)	Sex	Histological subtype	Initial stage	B symptoms (Y/N)	Extranodal (Y/N)	Bulky (Y/N)	Initial chemotherapy regimen	RTH (upfront)	Timing of relapse	Stage at relapse	Response after 2 cycles of IGEV	Risk at relapse	ASCT (Y/N)	Patients' status
1	12	F	NS	2	Y	N	Y	ABVD	No	Late	2	PR	SR	N	Alive
2	6	M	NS	4	Y	Y	NA	ABVD	No	Late	3	CR	LR	N	Alive
3	13	F	NS	2	N	N	Y	ABVD	No	Late	4	PR	SR	Y	Alive
4	4	M	NS	1	N	N	N	ABVD	Yes	Late	2	PR	SR	Y	Alive
5	5	M	NS	3	N	N	N	Euronet	No	Late	3	CR	LR	N	Alive
6	3	M	MC	3	N	N	N	Euronet	No	Late	2	PD	SR	N	Alive
7	12	F	NS	2	N	N	NA	Euronet	No	Late	4	PD	SR	Y	Lost to follow up
8	11	M	MC	4	Y	Y	NA	Euronet	No	Late	3	PR	SR	Y	Alive
9	12	F	NS	2	N	N	N	Euronet	No	Late	2	CR	LR	N	Alive
10	11	M	NS	4	Y	Y	Y	Euronet	Yes	Early	4	PR	SR	Y	Alive
11	14	M	NS	3	N	N	Y	Euronet	No	Early	4	SD	SR	Y	Alive
12	6	M	MC	3	Y	N	N	Euronet	Yes	Late	3	CR	SR	Y	Alive
13	15	F	NS	4	N	Y	Y	Euronet	Yes	Late	4	CR	SR	Y	Alive
14	7	M	MC	2	N	N	N	Euronet	No	Late	3	CR	LR	N	Alive
15	12	F	NS	2	Y	N	Y	Euronet	No	Late	2	PR	SR	Y	Alive
16	12	F	NS	2	Y	Y	N	Euronet	No	Late	2	CR	LR	N	Alive
17	16	M	MC	2	Y	N	Y	Euronet	No	Late	3	PR	SR	N	Alive
18	14	F	MC	2	Y	N	Y	Euronet	Yes	Early	4	SD	SR	Y	Alive
19	15	M	NS	4	N	Y	N	Euronet	No	Late	4	CR	SR	N	Alive
20	6	M	NS	4	Y	Y	Y	Euronet	Yes	Early	4	CR	SR	Y	Alive
21	17	M	NS	3	Y	N	Y	Euronet	Yes	Early	3	PR	SR	Y	Alive
22	16	M	NS	4	N	Y	N	Euronet	No	Refractory	4	PD	SR	Y	Alive
23	9	M	NS	4	Y	Y	N	Euronet	No	Refractory	3	CR	SR	Y	Alive
24	8	M	NS	4	N	Y	Y	Euronet	No	Early	4	PR	SR	Y	Alive
25	14	F	NS	2	N	N	N	Euronet	No	Early	3	CR	LR	N	Alive
26	11	M	NS	3	Y	N	Y	Euronet	No	Refractory	3	PR	SR	Y	Alive
27	17	M	NS	4	Y	Y	Y	Euronet	No	Refractory	4	PD	SR	Y	Alive
28	15	F	NS	3	Y	N	Y	Euronet	Yes	Refractory	4	SD	SR	N	Alive
29	11	F	NS	2	N	N	Y	Euronet	Yes	Early	3	SD	SR	Y	Alive
30	11	M	NS	2	Y	N	Y	Euronet	Yes	Refractory	2	CR	SR	Y	Dead
31	9	F	NS	4	N	Y	N	Euronet	No	Early	4	PR	SR	Y	Alive
32	11	F	NS	4	Y	Y	N	Euronet	No	Refractory	4	PD	SR	N	Lost to follow up
33	12	F	MC	4	Y	Y	Y	Euronet	No	Refractory	3	CR	SR	Y	Alive
34	11	M	NS	4	Y	Y	N	Euronet	No	Refractory	4	CR	SR	N	Alive
35	17	F	NS	4	N	Y	Y	Euronet	No	Refractory	2	PD	SR	N	Dead
36	6	M	MC	4	Y	Y	N	Euronet	No	Refractory	4	PD	SR	N	Lost to follow up
37	12	F	NS	2	Y	N	N	Euronet	No	Refractory	2	SD	SR	Y	Alive
38	16	M	NS	4	N	Y	N	Euronet	No	Refractory	4	CR	SR	Y	Alive
39	16	F	NS	4	Y	Y	NA	Euronet	No	Refractory	4	CR	SR	N	Alive
40	5	M	NS	2	N	N	N	Euronet	No	Refractory	2	CR	SR	Y	Alive

ASCT, autologous stem cell transplant; CR, complete response; F, female; IGEV, ifosfamide, gemcitabine, vinorelbine, prednisone; LR, low risk; M, male; MC, mixed cellularity; N, no; NA, not available; NS, nodular sclerosis; PD, progressive disease; PR, partial response; RTH, radiotherapy; SD, stable disease; SR, standard risk; Y, yes.